Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQYBSH)

Drug Name

PF-05231023 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Fibroblast growth factor-21 (FGF21)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pegozafermin	DM5D7VG	Hypertriglyceridemia	5C80.1	Phase 3	[3]
BMS-986036	DMIZKEC	Type-2 diabetes	5A11	Phase 2	[4]
FGF-21	DMB35UN	Type-2 diabetes	5A11	Discontinued in Phase 1/2	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor-21 (FGF21)	TTQ916P	FGF21_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01923389) Multiple Dose Study Of PF-05231023 In Obese Adult Subjects. U.S. National Institutes of Health.
2	Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate. Drug Metab Dispos. 2015 Jun;43(6):803-11.
3	Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):120-132.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028644)